AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method.
Through its diagnostic program, Biophage is developing a biosensor using an innovative nanotechnology. These nanosensors are based on impedance spectroscopy, an enabling technology that can detect and quantify microbial pathogens in real-time. The unique nanosensors will be built from various proprietary technologies already developed by Biophage (biocapture molecule: phages and antibodies) and by the Biotechnology Research Institute-NRC (signal generation and detection).
The company's lead product in development is Amorphous Nano-Hydroxyapaite Powder. Nano-structured hydroxyapatite has several advantages over hydroxyapatite of larger particle size in its use in bone tissue engineering due to its higher surface area and consequently higher reactivity, which offers better cellular response. In addition, nano-sized hydroxyapatite is useful as an effective surface modification agent for binding numerous biological molecules.
Nicoya Lifesciences is a company developing innovative medical diagnostic products using nanotechnology. Their goal is to provide consumers with new diagnostic tools that are affordable, connected, and intuitive, allowing them better control over their own health and wellness. Nicoya is using a proprietary nanoparticle sensor for blood protein biomarker diagnostics.